Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

abstract：:Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of health state utility values to inform the parameter inputs of decision-analytic modelling-based economic evaluations. Beyond the context of economic evaluation, evidence from systematic reviews and meta-analyses of health stat...

journal_title：PharmacoEconomics

authors： Petrou S,Kwon J,Madan J

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate...

journal_title：PharmacoEconomics

authors： Reboli AC,Rotstein C,Kett DH,Maschio M,Cartier S,Chambers R,Tarallo M

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Economic models are considered to be important, as they help evaluate the long-term impact of diabetes treatment. To date, it appears that no article has reviewed and critically appraised the cost-effectiveness models developed to evaluate new oral treatments [glucagon-like peptide-1 (GLP-1) receptor agonist...

journal_title：PharmacoEconomics

authors： Asche CV,Hippler SE,Eurich DT

更新日期：2014-01-01 00:00:00

abstract：:Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

journal_title：PharmacoEconomics

authors： Gupta AK

更新日期：1998-02-01 00:00:00

abstract：:This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

journal_title：PharmacoEconomics

authors： Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

更新日期：1997-09-01 00:00:00

abstract：:Community-acquired pneumonia (CAP) is a common diagnosis and care of CAP is responsible for significant healthcare expenditures, the majority of which are for patients who require hospitalisation. Studies have shown that significant variation exists among institutions with respect to antibacterial costs and length of ...

journal_title：PharmacoEconomics

authors： Brown PD

更新日期：2004-01-01 00:00:00

abstract：:Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

journal_title：PharmacoEconomics

authors： Freemantle N,Hessel F

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low d...

journal_title：PharmacoEconomics

authors： Wilson K,Marriott J,Fuller S,Lacey L,Gillen D

更新日期：2003-01-01 00:00:00

abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...

journal_title：PharmacoEconomics

authors： Scotland G,Waugh N,Royle P,McNamee P,Henderson R,Hollick R

更新日期：2011-11-01 00:00:00

abstract：:There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these ...

journal_title：PharmacoEconomics

authors： Kent S,Burn E,Dawoud D,Jonsson P,Østby JT,Hughes N,Rijnbeek P,Bouvy JC

更新日期：2020-12-18 00:00:00

abstract：:A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due ...

journal_title：PharmacoEconomics

authors： McCabe C,Dixon S

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Terkola R,Overton PM,Shalet N,Postma M

更新日期：2017-08-01 00:00:00

abstract：:The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

journal_title：PharmacoEconomics

authors： Vernon JA,Johnson SJ,Hughen WK,Trujillo A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of proton pump inhibitors (PPIs) reduces the risks of these digestive symptoms. We investigated ...

journal_title：PharmacoEconomics

authors： Takabayashi N,Murata K,Tanaka S,Kawakami K

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration. STUDY DESI...

journal_title：PharmacoEconomics

authors： Duda SH,Tepe G,Bala M,Luz O,Ziemer G,Ouriel K,Pusich B,Wiskirchen J,Claussen CD,Banz K

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：:The aim of this article was to perform a detailed methodological review of models used to estimate the cost effectiveness of drug treatment regimens for HIV infection in Europe and North America and assess the relationship between the different modeling approaches or key structural assumptions and the results. Electro...

journal_title：PharmacoEconomics

authors： Mauskopf J

更新日期：2013-11-01 00:00:00

abstract：OBJECTIVE:Our objective was to identify, among the information routinely collected on patients in intensive care units (ICUs), data that determine the total cost for a given patient. DESIGN:We developed a model that could help physicians in medical ICUs to estimate the cost of care for their patients when no cost data...

journal_title：PharmacoEconomics

authors： Chaix C,Durand-Zaleski I,Alberti C,Brun-Buisson C

更新日期：1999-06-01 00:00:00

abstract：:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

journal_title：PharmacoEconomics

authors： Tse G,Thompson D,Procyshyn RM

更新日期：2003-01-01 00:00:00

abstract：:Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Phillips P,Rotstein C,Puodziunas A,Shafran S,Garber G,Smaill F,Salit I,Miller M,Williams K,Conly J,Singer J,Ioannou S

更新日期：1998-05-01 00:00:00

abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

journal_title：PharmacoEconomics

authors： Neumann PJ,Fang CH,Cohen JT

更新日期：2009-01-01 00:00:00

abstract：:In this article, we model the behavior of a pharmaceutical firm that has marketing authorization for a new therapy believed to be a candidate for personalized use in a subset of patients, but that lacks information as to why a response is seen only in some patients. We characterize the optimal outcome-based reimbursem...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2018-07-01 00:00:00

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:To estimate the annual direct cost of managing erectile dysfunction (ED) to the UK National Health Service (NHS) and to examine the impact of the introduction of sildenafil in 1998 and Schedule 11 restrictions in 1999. DESIGN:A prevalence-based cost-of-illness approach was used. The period 1997 to 2000 was c...

journal_title：PharmacoEconomics

authors： Wilson EC,McKeen ES,Scuffham PA,Brown MC,Wylie K,Hackett G

更新日期：2002-01-01 00:00:00

abstract：:The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...

journal_title：PharmacoEconomics

authors： Van Bortel LM,Ament AJ

更新日期：1995-12-01 00:00:00

abstract：OBJECTIVE:To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of 74 years, a mean disease...

journal_title：PharmacoEconomics

authors： Green C,Picot J,Loveman E,Takeda A,Kirby J,Clegg A

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...

journal_title：PharmacoEconomics

authors： Najafzadeh M,Garces JA,Maciel A

更新日期：2017-12-01 00:00:00

abstract：:Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

journal_title：PharmacoEconomics

authors： Bermejo I,Tappenden P,Youn JH

更新日期：2017-11-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...

journal_title：PharmacoEconomics

authors： Bermejo I,Ren S,Simpson E,Clowes M,Scott DL,Young A,Stevenson M

更新日期：2018-12-01 00:00:00

abstract：:Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful measurements of complianc...

journal_title：PharmacoEconomics

authors： Urquhart J

更新日期：1999-03-01 00:00:00